JP2010516758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516758A5 JP2010516758A5 JP2009547177A JP2009547177A JP2010516758A5 JP 2010516758 A5 JP2010516758 A5 JP 2010516758A5 JP 2009547177 A JP2009547177 A JP 2009547177A JP 2009547177 A JP2009547177 A JP 2009547177A JP 2010516758 A5 JP2010516758 A5 JP 2010516758A5
- Authority
- JP
- Japan
- Prior art keywords
- mtd
- peptide
- protein
- group
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 37
- 230000000975 bioactive effect Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000026683 transduction Effects 0.000 description 11
- 238000010361 transduction Methods 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 2
- -1 antibodies Proteins 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88706007P | 2007-01-29 | 2007-01-29 | |
| US60/887,060 | 2007-01-29 | ||
| PCT/KR2008/000525 WO2008093982A1 (en) | 2007-01-29 | 2008-01-29 | Novel macromolecule transduction domains and methods for identification and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013207349A Division JP2014057586A (ja) | 2007-01-29 | 2013-10-02 | 巨大分子伝達ドメインならびにその同定方法および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010516758A JP2010516758A (ja) | 2010-05-20 |
| JP2010516758A5 true JP2010516758A5 (cg-RX-API-DMAC7.html) | 2011-04-21 |
| JP5518488B2 JP5518488B2 (ja) | 2014-06-11 |
Family
ID=39674245
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009547177A Active JP5518488B2 (ja) | 2007-01-29 | 2008-01-29 | 巨大分子伝達ドメインならびにその同定方法および使用 |
| JP2013207349A Pending JP2014057586A (ja) | 2007-01-29 | 2013-10-02 | 巨大分子伝達ドメインならびにその同定方法および使用 |
| JP2015090144A Active JP6140759B2 (ja) | 2007-01-29 | 2015-04-27 | 巨大分子伝達ドメインならびにその同定方法および使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013207349A Pending JP2014057586A (ja) | 2007-01-29 | 2013-10-02 | 巨大分子伝達ドメインならびにその同定方法および使用 |
| JP2015090144A Active JP6140759B2 (ja) | 2007-01-29 | 2015-04-27 | 巨大分子伝達ドメインならびにその同定方法および使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8629097B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2129682A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5518488B2 (cg-RX-API-DMAC7.html) |
| KR (18) | KR20090103957A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101616928B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008211854C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2676797C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008093982A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| EP2438962A3 (en) | 2006-02-13 | 2012-07-18 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| US8158415B2 (en) | 2007-02-27 | 2012-04-17 | Procell Therapeutics Inc. | Combined use of cell permeable Nanog and Oct4 for increasing self-renewal and suppressing differentiation of stem cells |
| KR100887266B1 (ko) * | 2007-09-04 | 2009-03-06 | 주식회사 프로셀제약 | 세포투과성 ｐ１８ 재조합 단백질, 이를 코딩하는폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암조성물 |
| KR101192860B1 (ko) * | 2007-09-04 | 2012-11-15 | 주식회사 프로셀제약 | 세포투과성 Ｎｍ23 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 암 전이 억제용 조성물 |
| EP2209892A2 (en) * | 2007-11-06 | 2010-07-28 | Procell Therapeutics Inc. | Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same |
| WO2009145489A2 (ko) | 2008-04-04 | 2009-12-03 | 주식회사 프로셀제약 | 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 |
| WO2010104357A2 (ko) | 2009-03-12 | 2010-09-16 | 주식회사 프로셀제약 | 환자맞춤형 줄기세포치료를 위한 세포투과성 역분화 전사인자를 이용한 유도만능줄기세포 확립 |
| DK3252068T3 (da) | 2009-10-12 | 2025-08-25 | Larry J Smith | Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro |
| TW201302800A (zh) * | 2011-06-10 | 2013-01-16 | Oncotherapy Science Inc | Ｓｅｍａ５ｂ胜肽及含其之疫苗 |
| KR102067760B1 (ko) | 2011-08-16 | 2020-01-17 | 삼성전자주식회사 | 세포 내 전달용 단백질 복합체 및 그의 용도 |
| WO2013077681A1 (ko) * | 2011-11-23 | 2013-05-30 | 주식회사 프로셀제약 | 세포내 분자 전송 펩티드를 이용한 피부 생리 활성 분자의 경피 전달시스템 |
| EP2784081B1 (en) | 2011-11-23 | 2017-02-01 | Procell Therapeutics Inc. | Development of novel macromolecule transduction domain with improved cell permeability and method for using same |
| KR101258279B1 (ko) * | 2011-11-23 | 2013-04-25 | 주식회사 프로셀제약 | 세포 투과능을 개선한 개량형 신규 거대 분자 전달 도메인 개발 및 이의 이용방법 |
| KR20150014483A (ko) | 2012-05-11 | 2015-02-06 | 주식회사 카엘젬백스 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 |
| EP2875826B1 (en) | 2012-05-11 | 2017-08-23 | KAEL-GemVax Co.,Ltd | Composition for preventing or treating sepsis |
| WO2014005219A1 (en) * | 2012-07-02 | 2014-01-09 | Iprogen Biotech Inc. | Intracellular protein delivery |
| EP2873678B8 (en) | 2012-07-11 | 2024-07-17 | Gemvax & Kael Co., Ltd. | Conjugate comprising a cell-penetrating peptide and compositions comprising same |
| EP2875051B1 (en) | 2012-07-19 | 2019-02-20 | Daiichi Sankyo Company, Limited | Anti-siglec-15 antibodies |
| US9631184B2 (en) | 2012-09-19 | 2017-04-25 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| ES2999332T3 (en) * | 2012-09-19 | 2025-02-25 | Gemvax & Kael Co Ltd | Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate |
| ES2716870T3 (es) | 2013-04-19 | 2019-06-17 | Gemvax & Kael Co Ltd | Composición para el tratamiento y prevención de lesión isquémica |
| CN105535931A (zh) | 2013-06-07 | 2016-05-04 | 凯尔杰姆维克斯有限公司 | 在癌症免疫疗法中有用的生物标记 |
| ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
| GB201315321D0 (en) * | 2013-08-28 | 2013-10-09 | Koninklijke Nederlandse Akademie Van Wetenschappen | Transduction Buffer |
| BR112016008331B1 (pt) | 2013-10-23 | 2023-01-31 | Sang Jae Kim | Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp |
| WO2015076621A1 (ko) | 2013-11-22 | 2015-05-28 | 주식회사 카엘젬백스 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
| WO2015123750A1 (en) | 2014-02-20 | 2015-08-27 | Cura Health Inc. | Transdermal composition for treating pain |
| JP6420459B2 (ja) | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー，リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
| CN106659149B (zh) | 2014-04-30 | 2020-05-19 | 珍白斯凯尔有限公司 | 用于器官、组织或细胞移植的组合物、试剂盒和移植方法 |
| CA2949653C (en) * | 2014-05-29 | 2019-12-17 | Procell Therapeutics Inc. | Novel cell penetrating peptide, conjugate thereof with botulinum toxin, and use thereof |
| CA2957501C (en) | 2014-08-17 | 2020-08-11 | Cellivery Therapeutics, Inc. | Advanced macromolecule transduction domain (amtd) sequences for improvement of cell-permeability, polynucleotides encoding the same, method to identify the unique features of amtds comprising the same, method to develop the amtd sequences comprising the same |
| US20160060313A1 (en) * | 2014-08-27 | 2016-03-03 | Daewoong Jo | Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Angiogenic Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Angiogenic Compositions Comprising the Same |
| CN104548073B (zh) * | 2014-12-12 | 2017-08-11 | 浙江大学 | Prx I重组蛋白在制备抗细菌性败血症药物中的应用 |
| EP3237434A1 (en) * | 2014-12-22 | 2017-11-01 | F. Hoffmann-La Roche AG | Cell penetrating peptides |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| EP3263122B1 (en) | 2015-02-27 | 2020-05-06 | Gemvax & Kael Co., Ltd. | Peptide for preventing hearing loss, and composition comprising same |
| ES2879641T3 (es) | 2015-05-26 | 2021-11-22 | Gemvax & Kael Co Ltd | Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen |
| WO2017003267A1 (ko) | 2015-07-02 | 2017-01-05 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| US20170029798A1 (en) | 2015-07-27 | 2017-02-02 | Cellivery Therapeutics, Inc. | Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD) |
| EP3334756B1 (en) | 2015-08-10 | 2020-06-17 | Cellivery Therapeutics, Inc. | Improved cell-permeable cre (icp-cre) recombinant protein and use thereof |
| EP3334755B1 (en) * | 2015-08-10 | 2020-04-08 | Cellivery Therapeutics, Inc. | Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof |
| WO2017030323A1 (en) | 2015-08-18 | 2017-02-23 | Cellivery Therapeutics, Inc. | Cell-permeable (cp)-δsocs3 recombinant protein and uses thereof |
| GB201521101D0 (en) | 2015-11-30 | 2016-01-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Transduction buffer |
| KR101800407B1 (ko) * | 2016-04-04 | 2017-11-22 | 건국대학교 산학협력단 | 비단뱀으로부터 분리한 신규한 항균 펩타이드 및 이의 발굴 방법 |
| US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| IL265920B2 (en) * | 2016-10-12 | 2024-05-01 | Feldan Bio Inc | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| WO2018074558A1 (ja) | 2016-10-23 | 2018-04-26 | デンカ株式会社 | 複合ポリペプチド単量体、細胞浸透機能を有する当該複合ポリペプチドの単量体の会合体、及び、当該会合体を有効成分とする皮下、皮内、経皮又は筋肉内投与用ノロウイルスコンポーネントワクチン |
| CN106995487B (zh) * | 2017-04-17 | 2019-12-03 | 扬州大学 | 源于鸡传染性贫血病毒VP1-aa 23-43多肽作为高效细胞穿膜肽的应用 |
| CN106831957B (zh) * | 2017-04-17 | 2019-12-03 | 扬州大学 | 一种源于鸡传染性贫血病毒VP1-aa 1-19多肽作为高效细胞穿膜肽的应用 |
| WO2019108047A2 (ko) | 2017-12-01 | 2019-06-06 | 주식회사 굳티셀 | 탈모의 예방 또는 치료용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1031959C (zh) * | 1991-04-11 | 1996-06-05 | 住友电气工业株式会社 | 测量涂层状态的方法和设备 |
| US5807746A (en) * | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
| US6248558B1 (en) | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
| AU2002240448A1 (en) | 2001-02-15 | 2002-08-28 | Baylor College Of Medicine | Use of cell penetrating peptides to generate antitumor immunity |
| DE60329089D1 (de) * | 2002-03-29 | 2009-10-15 | Creagene Inc | Zytoplasmatische transduktionspeptide und deren verwendungen |
| US6835810B2 (en) * | 2002-05-13 | 2004-12-28 | Geneshuttle Biopharma, Inc. | Fusion protein for use as vector |
| SE0201863D0 (en) * | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US20070154437A1 (en) | 2002-09-03 | 2007-07-05 | Pingfan Rao | Peptide-tagged proteins and methods of making and using thereof |
| US20040043463A1 (en) | 2002-09-03 | 2004-03-04 | Pingfan Rao | Peptide-tagged proteins and compositions for regulating features of the skin or hair; methods of making, and methods of using thereof |
| US7166692B2 (en) | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
-
2008
- 2008-01-29 JP JP2009547177A patent/JP5518488B2/ja active Active
- 2008-01-29 WO PCT/KR2008/000525 patent/WO2008093982A1/en not_active Ceased
- 2008-01-29 CN CN200880003468.9A patent/CN101616928B/zh active Active
- 2008-01-29 AU AU2008211854A patent/AU2008211854C1/en active Active
- 2008-01-29 KR KR1020097017564A patent/KR20090103957A/ko not_active Ceased
- 2008-01-29 CA CA2676797A patent/CA2676797C/en active Active
- 2008-01-29 EP EP08712219A patent/EP2129682A4/en not_active Withdrawn
- 2008-01-29 EP EP14184544.6A patent/EP2837636B1/en active Active
- 2008-01-29 US US12/524,935 patent/US8629097B2/en active Active
-
2013
- 2013-10-02 JP JP2013207349A patent/JP2014057586A/ja active Pending
- 2013-11-27 US US14/091,823 patent/US9040477B2/en active Active
-
2015
- 2015-04-27 JP JP2015090144A patent/JP6140759B2/ja active Active
-
2016
- 2016-03-31 KR KR1020160039707A patent/KR102217269B1/ko active Active
-
2020
- 2020-02-28 KR KR1020200025221A patent/KR102217277B1/ko active Active
- 2020-02-28 KR KR1020200025225A patent/KR102217304B1/ko active Active
- 2020-02-28 KR KR1020200025234A patent/KR102217331B1/ko active Active
- 2020-02-28 KR KR1020200025222A patent/KR102217281B1/ko active Active
- 2020-02-28 KR KR1020200025220A patent/KR102217274B1/ko active Active
- 2020-02-28 KR KR1020200025231A patent/KR102217321B1/ko active Active
- 2020-02-28 KR KR1020200025226A patent/KR102217308B1/ko active Active
- 2020-02-28 KR KR1020200025235A patent/KR102254723B1/ko active Active
- 2020-02-28 KR KR1020200025229A patent/KR102217317B1/ko active Active
- 2020-02-28 KR KR1020200025224A patent/KR102217299B1/ko active Active
- 2020-02-28 KR KR1020200025233A patent/KR102217325B1/ko active Active
- 2020-02-28 KR KR1020200025227A patent/KR102217310B1/ko active Active
- 2020-02-28 KR KR1020200025230A patent/KR102217320B1/ko active Active
- 2020-02-28 KR KR1020200025223A patent/KR102217295B1/ko active Active
- 2020-02-28 KR KR1020200025228A patent/KR102217313B1/ko active Active
- 2020-02-28 KR KR1020200025232A patent/KR102217324B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516758A5 (cg-RX-API-DMAC7.html) | ||
| KR100981356B1 (ko) | 신호서열 및 변이된 신호서열로 디자인된 분비증강자에의한 원래 형태의 수용성 재조합 단백질 생산 방법 | |
| US10239922B2 (en) | Fusion proteins of superfolder green fluorescent protein and use thereof | |
| CN110511280B (zh) | 一种透皮重组纤连蛋白及其应用 | |
| EP2351775B1 (en) | Fusion protein comprising ubiquitin or ubiquitin-like protein, membrane translocation sequence and biologically active molecule and use thereof | |
| US8859507B2 (en) | Protein complex for intracellular delivery and uses thereof | |
| WO2014165093A2 (en) | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto | |
| JP2007508846A5 (cg-RX-API-DMAC7.html) | ||
| CN101134780A (zh) | 阻断nr2b信号通路的多肽类似物及其制备方法和药物用途 | |
| CN107698684A (zh) | 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白 | |
| JPH0797995B2 (ja) | ペプチド類の製造法 | |
| WO2022241831A1 (zh) | 多肽的制备方法 | |
| CN101240033A (zh) | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 | |
| CN1311819A (zh) | 胰岛素样生长因子结合蛋白变体 | |
| CN101343327A (zh) | 一种抗病毒蛋白质及其应用 | |
| CN102311501A (zh) | 含有glp-1或其类似物的融合蛋白、制备方法及其应用 | |
| US20190352365A1 (en) | Expression construct and method for producing proteins of interest | |
| CN109776653B (zh) | 一种人血清白蛋白黏附肽及其应用 | |
| CN102174110B (zh) | 狂犬病毒糖蛋白衍生肽及其应用 | |
| CN105884901B (zh) | 具持续控制血糖含量功能的重组人血清白蛋白/胰高糖素类肽融合蛋白 | |
| CN102993309B (zh) | 一种人生长素融合蛋白TAT-hGH及其制备方法和应用 | |
| WO2022192687A1 (en) | Synthetic promoters for gene therapy and protein expression | |
| KR20220117091A (ko) | 생체내 세포에서 합성 및 분비되고 세포로 투과하는 관심 폴리펩타이드를 코딩하는 발현카세트 및 이의 용도 | |
| JP2022548598A (ja) | 組換え治療用ペプチドの発現のためのｎ末端伸長配列 | |
| US20240166696A1 (en) | Scaffolds For Inducing Antibody Responses Against Antigenic Sites |